Background Randomised trials of rituximab maintenance (MR) for patients with follicular
lymphoma support improved progression-free survival (PFS), but the effect on overall …

Background Follicular lymphoma is characterized by slow growth and an initially high rate of
response to treatment, but patients typically relapse and experience progressive disease …

In a previous systematic review and meta-analysis of five randomized controlled trials
comparing rituximab maintenance with no maintenance (observation or rituximab at …

PURPOSE The PRIMA study (ClinicalTrials. gov identifier: NCT00140582) established that 2
years of rituximab maintenance after first-line immunochemotherapy significantly improved …

Purpose Rituximab maintenance therapy has been shown to improve progression-free
survival in patients with follicular lymphoma; however, the optimal duration of maintenance …

Whilst recent advances in the treatment of follicular lymphoma (FL) have improved the
outlook for many patients, relapses still occur and the search continues for strategies to …

Background Patients with follicular lymphoma can have long survival times, but disease
progression typically occurs 3–5 years after initial treatment. We assessed the potential …

Abstract The Swiss Group for Clinical Cancer Research (SAKK) conducted the SAKK 35/03
randomized trial (NCT00227695) to investigate different rituximab monotherapy schedules …

E1496 is a phase III trial designed to evaluate the ability of 2 years (yr) of maintenance
rituximab (MR) to prolong progression-free survival (PFS) after CVP (cyclophosphamide 1 …

Background Rituximab maintenance has been shown to be effective in patients with
follicular lymphoma. The optimal duration of maintenance treatment remains unknown …